Spyre Therapeutics, Inc. SYRE Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesAndOtherLiabilities.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s accrued expenses?
- Spyre Therapeutics, Inc. (SYRE) reported accrued expenses of $29.16M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s accrued expenses changed year-over-year?
- Spyre Therapeutics, Inc.'s accrued expenses increased by 34.8% year-over-year, from $21.63M to $29.16M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s accrued expenses?
- Over 5 years (2020 to 2025), Spyre Therapeutics, Inc.'s accrued expenses has grown at a 14.2% compound annual growth rate (CAGR), from $13.87M to $26.95M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.